Daewoong to conduct phase I trial for investigational neuropathic pain product

Published: 2008-10-31 06:54:00

Updated: 2008-10-31 06:54:00

Daewoong Pharm says it will conduct a phase I study for its investigational neuropathic pain product (DWP05195) after approval from the Korea Food and Drug Administration.

According to the company, the phase I study will be conducted in Seoul National University Hospital in order to determine ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK